Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Dec 02, 2022 12:47pm
313 Views
Post# 35146835

RE:RE:RE:RE:RE:RE:RE:CG Oncology NMIBC data

RE:RE:RE:RE:RE:RE:RE:CG Oncology NMIBC data

On top of our best in class single agent data so far, the fact that this a pretty much a One and Done treatment and see you in 6 months for a maintenance should be used to push the FDA for BTD. Needs of Elderly patients must be taken into account.  This option gives them freedom and much less morbidity of having weekly instillations with all of the swelling and pain and possible infections which the procedure involves.  IMHO 


ScienceFirst wrote:

 


_______________


There has been innovations in all industries, including oncology.  And this wil continue.  No plot theories here. Just facts, R&D, innovations and competition.

Public Health budgets are about 50% of all Canadian provinces budgets.  So huge incentives to lower them, especially with the growing population of elderly people.  Ontario government that sponsored our technology that will spur medical tourism will of course push for such treatment if deemed superior.

Private insurance companies are other parties that will push for it too.

Laparoscopy, arteoscopy, 1-day surgeries, etc ... are all innovative procedures that have been integrated in the health systems.  TLT has done the heavy lifting to bring PDT/PDC to bedside and mainstream thanks to a molecule with impressive attributes.  It could allow big pharmas to treat way more patients in early stage instead of having too many dying because of lack of efficient treatments.  



<< Previous
Bullboard Posts
Next >>